• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Brexanolone (Zulresso) for Postpartum Depression

Brexanolone (Zulresso) for Postpartum Depression

July 3, 2019
Talia Puzantian, Chris Aiken, MD, and Chris Aiken
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Talia Puzantian, PharmD, BCPP Chris Aiken, MD Drs. Puzantian and Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

On March 19, 2019, the FDA approved brexanolone (Zulresso), the first medication for postpartum depression (PPD). Delivered by intravenous injection, brexanolone is an analogue of the hormone allopregnanolone. Allopregnanolone levels fall abruptly after childbirth, which is thought to contribute to PPD by destabilizing GABAA receptors.


We covered brexanolone’s mechanism in our January 2019 issue and have some practical updates for readers who want to start using it.


How is it delivered?
As a one-time, 60-hour IV infusion at 60–90 µg/kg/hour.


How effective is it?
To achieve remission, the number needed to treat with brexanolone is 5–8. The efficacy is based on three positive randomized, double-blind, placebo-controlled trials involving 267 women with moderate or severe PPD (Meltzer-Brody S et al, Lancet 2018;392:1058–1070).


Are the effects long lasting?
We only have data up to 30 days, and 94% of patients who responded maintained their response at that point.


Are there side effects?
The main risk is excessive sedation (2%–4%) and loss of consciousness. Otherwise, side effects were similar in the placebo and brexanolone groups and included dry mouth, loss of consciousness, and flushing.


Can women breastfeed during the infusion?
Possibly. We have data on only 12 women, and brexanolone had a low rate of transfer to the infant in that group (1%–2% of maternal weight-adjusted dosage).


Who can administer it?
Brexanolone is a schedule IV controlled substance and requires both the patient and health care provider to enroll in a REMS program (see www.thecarlatreport.com/REMS). Because of the risk of excessive sedation, brexanolone must be administered with continuous pulse oximetry during the 60-hour infusion. If hypoxia occurs, the infusion should be stopped and not restarted. Patients can engage with their children during the infusion, but they are required to be accompanied by another adult because of the risk of sedation.


What is the cost?
$34,000 for the drug without insurance, plus costs associated with administration and monitoring. Insurers have not developed their coverage policies yet, but it’s likely they will require failure of antidepressant trials before authorizing it.


How can I find a brexanolone center for my patient?
Sage Therapeutics keeps a list of certified providers at 844-472-4379.


TCPR’S Take
Brexanolone’s main advantage is speed. Each month of depression takes a toll on infant development and maternal attachment, so a medication that works within a few days is worth considering. The main drawback is the cost and lengthy infusion period. While the one-time treatment will be appealing to some patients, we need more research to know if these recoveries can last beyond 30 days.

General Psychiatry
KEYWORDS depression depressive_disorder pharmacology postpartum-depression pregnancy
    Puzantian 150x150
    Talia Puzantian

    A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness

    More from this author
    Aiken
    Chris Aiken, MD

    Amphetamine vs Methylphenidate

    More from this author
    Chris Aiken

    A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness

    More from this author
    www.thecarlatreport.com
    Issue Date: July 3, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Side Effects Part I, TCPR, June/July 2019
    Mood Stabilizers and Stroke Risk in Bipolar Disorder
    Lithium in Geriatric Depression
    New Augmentation Strategies in OCD
    Esketamine Gets FDA Approval
    Risk Evaluation and Mitigation Strategy (REMS) Programs
    Medication Side Effects: Nausea, Sweating, and Dry Mouth
    Are Auditory Hallucinations Ever Normal?
    Brexanolone (Zulresso) for Postpartum Depression
    A New Dopamine and Norepinephrine Reuptake Inhibitor for Excessive Sleepiness
    A New Proposal for SSRI Withdrawal
    SSRI withdrawal symptoms
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.